Cochrane Abstracts
Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Cabergoline Versus Bromocriptine for Levodopa‐induced Complications in Parkinson's Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438795/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson&apos.
Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438795/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson&apos. Accessed February 15, 2026.
Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438795/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson&apos
Cabergoline Versus Bromocriptine for Levodopa‐induced Complications in Parkinson's Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 February 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438795/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson&apos.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease
ID - 438795
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438795/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson&apos
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
